← Back to Clinical Trials
Recruiting NCT03492060

NCT03492060 Longitudinal Study of Neurogenetic Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03492060
Status Recruiting
Phase
Sponsor Columbia University
Condition Neurodevelopmental Disorders
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2018-06-13
Primary Completion 2030-12

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2018-06-13 with a primary completion date of 2030-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to analyze patterns in individuals with hnRNP (and other) genetic variants, including their neurological comorbidities, other medical problems and any treatment. The investigators will maintain an ongoing database of medical data that is otherwise being collected for routine medical care. The investigators will also collect data prospectively in the form of questionnaires, neuropsychological assessments, motor assessments, and electroencephalography to examine the landscape of deleterious variants in these genes.

Eligibility Criteria

Inclusion Criteria: * Individuals must have had whole genome/exome sequencing and have a confirmed variant in any gene. Exclusion Criteria: * Subjects who cannot provide genetic confirmation of a predicted deleterious variant in any gene.

Contact & Investigator

Central Contact

Jennifer M. Bain, MD, PhD

✉ jb3634@cumc.columbia.edu

📞 646-426-3876

Principal Investigator

Jennifer M. Bain, MD, PhD

PRINCIPAL INVESTIGATOR

Columbia University

Frequently Asked Questions

Who can join the NCT03492060 clinical trial?

This trial is open to participants of all sexes, studying Neurodevelopmental Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03492060 currently recruiting?

Yes, NCT03492060 is actively recruiting participants. Contact the research team at jb3634@cumc.columbia.edu for enrollment information.

Where is the NCT03492060 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT03492060 clinical trial?

NCT03492060 is sponsored by Columbia University. The principal investigator is Jennifer M. Bain, MD, PhD at Columbia University. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology